ID   EGFR_HUMAN              Reviewed;        1210 AA.
AC   P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2;
AC   Q9GZX1; Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   05-OCT-2010, entry version 165.
DE   RecName: Full=Epidermal growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-ErbB-1;
DE   AltName: Full=Receptor tyrosine-protein kinase erbB-1;
DE   Flags: Precursor;
GN   Name=EGFR; Synonyms=ERBB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=84219729; PubMed=6328312; DOI=10.1038/309418a0;
RA   Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W.,
RA   Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J.,
RA   Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H.;
RT   "Human epidermal growth factor receptor cDNA sequence and aberrant
RT   expression of the amplified gene in A431 epidermoid carcinoma cells.";
RL   Nature 309:418-425(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   MEDLINE=95382957; PubMed=7654368; DOI=10.1002/mrd.1080410205;
RA   Ilekis J.V., Stark B.C., Scoccia B.;
RT   "Possible role of variant RNA transcripts in the regulation of
RT   epidermal growth factor receptor expression in human placenta.";
RL   Mol. Reprod. Dev. 41:149-156(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   MEDLINE=97078686; PubMed=8918811; DOI=10.1093/nar/24.20.4050;
RA   Reiter J.L., Maihle N.J.;
RT   "A 1.8 kb alternative transcript from the human epidermal growth
RT   factor receptor gene encodes a truncated form of the receptor.";
RL   Nucleic Acids Res. 24:4050-4056(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RC   TISSUE=Placenta;
RX   MEDLINE=97256547; PubMed=9103388; DOI=10.1006/gyno.1996.4526;
RA   Ilekis J.V., Gariti J., Niederberger C., Scoccia B.;
RT   "Expression of a truncated epidermal growth factor receptor-like
RT   protein (TEGFR) in ovarian cancer.";
RL   Gynecol. Oncol. 65:36-41(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Placenta;
RX   MEDLINE=21100872; PubMed=11161793; DOI=10.1006/geno.2000.6341;
RA   Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J.,
RA   Schehl Sinclair C., Pearsall R.S., Green P.J., Yee D., Lampland A.L.,
RA   Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D.,
RA   Maihle N.J.;
RT   "Comparative genomic sequence analysis and isolation of human and
RT   mouse alternative EGFR transcripts encoding truncated receptor
RT   isoforms.";
RL   Genomics 71:1-20(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Xu L., Hong A., He X.;
RT   "Cloning of the cDNA for a short EGF receptor from human placenta.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-98; ARG-266;
RP   LYS-521; ILE-674; GLY-962 AND PRO-988.
RG   NIEHS SNPs program;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 575-687.
RA   Reiter J.L., Threadgill D.W., Danielsen A.J., Schehl C.M.,
RA   Lampland A.L., Balasubramaniam S., Crossley T.O., Magnuson T.R.,
RA   Maihle N.J.;
RT   "Human and mouse alternative EGFR transcripts encoding only the
RT   extracellular domain of the receptor.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-924.
RX   MEDLINE=84196372; PubMed=6326261; DOI=10.1126/science.6326261;
RA   Lin C.R., Chen W.S., Kruiger W., Stolarsky L.S., Weber W., Evans R.M.,
RA   Verma I.M., Gill G.N., Rosenfeld M.G.;
RT   "Expression cloning of human EGF receptor complementary DNA: gene
RT   amplification and three related messenger RNA products in A431
RT   cells.";
RL   Science 224:843-848(1984).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 150-962.
RX   MEDLINE=84245835; PubMed=6330563; DOI=10.1038/309806a0;
RA   Xu Y.H., Ishii S., Clark A.J.L., Sullivan M., Wilson R.K., Ma D.P.,
RA   Roe B.A., Merlino G.T., Pastan I.;
RT   "Human epidermal growth factor receptor cDNA is homologous to a
RT   variety of RNAs overproduced in A431 carcinoma cells.";
RL   Nature 309:806-810(1984).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1210.
RX   MEDLINE=85046483; PubMed=6093780;
RA   Simmen F.A., Gope M.L., Schulz T.Z., Wright D.A., Carpenter G.,
RA   O'Malley B.W.;
RT   "Isolation of an evolutionarily conserved epidermal growth factor
RT   receptor cDNA from human A431 carcinoma cells.";
RL   Biochem. Biophys. Res. Commun. 124:125-132(1984).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   MEDLINE=88217333; PubMed=3329716;
RA   Haley J.D., Whittle N., Bennett P., Kinchington D., Ullrich A.,
RA   Waterfield M.D.;
RT   "The human EGF receptor gene: structure of the 110 kb locus and
RT   identification of sequences regulating its transcription.";
RL   Oncogene Res. 1:375-396(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   MEDLINE=91107677; PubMed=1988448;
RA   Haley J.D., Waterfield M.D.;
RT   "Contributory effects of de novo transcription and premature
RT   transcript termination in the regulation of human epidermal growth
RT   factor receptor proto-oncogene RNA synthesis.";
RL   J. Biol. Chem. 266:1746-1753(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   MEDLINE=85270438; PubMed=2991899; DOI=10.1073/pnas.82.15.4920;
RA   Ishii S., Xu Y.H., Stratton R.H., Roe B.A., Merlino G.T., Pastan I.;
RT   "Characterization and sequence of the promoter region of the human
RT   epidermal growth factor receptor gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4920-4924(1985).
RN   [15]
RP   NUCLEOTIDE SEQUENCE OF 25-49.
RX   MEDLINE=84172183; PubMed=6324343; DOI=10.1126/science.6324343;
RA   Weber W., Gill G.N., Spiess J.;
RT   "Production of an epidermal growth factor receptor-related protein.";
RL   Science 224:294-297(1984).
RN   [16]
RP   PROTEIN SEQUENCE OF 540.
RA   Kohda D.;
RL   Submitted (SEP-1997) to UniProtKB.
RN   [17]
RP   PROTEIN SEQUENCE OF 687-705; 986-998; 1000-1023; 1026-1030 AND
RP   1068-1077, AND PHOSPHORYLATION AT THR-693; SER-695; SER-1070 AND
RP   SER-1071.
RX   MEDLINE=88330814; PubMed=3138233;
RA   Heisermann G.J., Gill G.N.;
RT   "Epidermal growth factor receptor threonine and serine residues
RT   phosphorylated in vivo.";
RL   J. Biol. Chem. 263:13152-13158(1988).
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [19]
RP   PROTEIN SEQUENCE OF 740-744 AND 746-747.
RX   MEDLINE=85182650; PubMed=2985580;
RA   Russo M.W., Lukas T.J., Cohen S., Staros J.V.;
RT   "Identification of residues in the nucleotide binding site of the
RT   epidermal growth factor receptor/kinase.";
RL   J. Biol. Chem. 260:5205-5208(1985).
RN   [20]
RP   PROTEIN SEQUENCE OF 861-875 AND 914-932, UBIQUITINATION AT LYS-716;
RP   LYS-737; LYS-754; LYS-867; LYS-929 AND LYS-970, AND MASS SPECTROMETRY.
RX   PubMed=16543144; DOI=10.1016/j.molcel.2006.02.018;
RA   Huang F., Kirkpatrick D., Jiang X., Gygi S.P., Sorkin A.;
RT   "Differential regulation of EGF receptor internalization and
RT   degradation by multiubiquitination within the kinase domain.";
RL   Mol. Cell 21:737-748(2006).
RN   [21]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   MEDLINE=98225196; PubMed=9556602; DOI=10.1074/jbc.273.18.11150;
RA   Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D.;
RT   "Disulfide bond structure of human epidermal growth factor receptor.";
RL   J. Biol. Chem. 273:11150-11157(1998).
RN   [22]
RP   RECEPTOR ACTIVITY.
RX   MEDLINE=84191554; PubMed=6325948; DOI=10.1038/309270a0;
RA   Mroczkowski B., Mosig G., Cohen S.;
RT   "ATP-stimulated interaction between epidermal growth factor receptor
RT   and supercoiled DNA.";
RL   Nature 309:270-273(1984).
RN   [23]
RP   REVIEW.
RX   MEDLINE=87297456; PubMed=3039909;
RX   DOI=10.1146/annurev.bi.56.070187.004313;
RA   Carpenter G.;
RT   "Receptors for epidermal growth factor and other polypeptide
RT   mitogens.";
RL   Annu. Rev. Biochem. 56:881-914(1987).
RN   [24]
RP   LIGAND-BINDING.
RX   MEDLINE=90003233; PubMed=2790960; DOI=10.1016/0092-8674(89)90867-2;
RA   Chen W.S., Lazar C.S., Lund K.A., Welsh J.B., Chang C.P., Walton G.M.,
RA   Der C.J., Wiley H.S., Gill G.N., Rosenfeld M.G.;
RT   "Functional independence of the epidermal growth factor receptor from
RT   a domain required for ligand-induced internalization and calcium
RT   regulation.";
RL   Cell 59:33-43(1989).
RN   [25]
RP   PHOSPHORYLATION.
RX   MEDLINE=89278137; PubMed=2543678;
RA   Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M.,
RA   Howk R., Givol D., Ullrich A., Schlessinger J.;
RT   "All autophosphorylation sites of epidermal growth factor (EGF)
RT   receptor and HER2/neu are located in their carboxyl-terminal tails.
RT   Identification of a novel site in EGF receptor.";
RL   J. Biol. Chem. 264:10667-10671(1989).
RN   [26]
RP   INTERACTION WITH CBL.
RX   PubMed=7657591; DOI=10.1074/jbc.270.35.20242;
RA   Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
RT   "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product
RT   and association with epidermal growth factor (EGF) receptor upon EGF
RT   stimulation.";
RL   J. Biol. Chem. 270:20242-20245(1995).
RN   [27]
RP   GLYCOSYLATION AT ASN-128; ASN-175; ASN-413; ASN-444 AND ASN-528.
RX   MEDLINE=96398132; PubMed=8962717;
RA   Smith K.D., Davies M.J., Bailey D., Renouf D.V., Hounsell E.F.;
RT   "Analysis of the glycosylation patterns of the extracellular domain of
RT   the epidermal growth factor receptor expressed in Chinese hamster
RT   ovary fibroblasts.";
RL   Growth Factors 13:121-132(1996).
RN   [28]
RP   INTERACTION WITH AP2M1.
RX   PubMed=10228163; DOI=10.1093/emboj/18.9.2489;
RA   Nesterov A., Carter R.E., Sorkina T., Gill G.N., Sorkin A.;
RT   "Inhibition of the receptor-binding function of clathrin adaptor
RT   protein AP-2 by dominant-negative mutant mu2 subunit and its effects
RT   on endocytosis.";
RL   EMBO J. 18:2489-2499(1999).
RN   [29]
RP   GLYCOSYLATION AT ASN-56; ASN-352; ASN-361; ASN-568 AND ASN-603.
RX   MEDLINE=20198209; PubMed=10731668;
RA   Sato C., Kim J.-H., Abe Y., Saito K., Yokoyama S., Kohda D.;
RT   "Characterization of the N-oligosaccharides attached to the atypical
RT   Asn-X-Cys sequence of recombinant human epidermal growth factor
RT   receptor.";
RL   J. Biochem. 127:65-72(2000).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [31]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND ERBB2, IDENTIFICATION IN
RP   A COMPLEX WITH PIK3C2B AND ERBB2, INTERACTION WITH PIK3C2B, AND
RP   MUTAGENESIS OF TYR-1016; TYR-1092; TYR-1110; TYR-1172 AND TYR-1197.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [32]
RP   INTERACTION WITH RIPK1.
RX   MEDLINE=21153697; PubMed=11116146; DOI=10.1074/jbc.M008458200;
RA   Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S.,
RA   Vartanian T.;
RT   "The epidermal growth factor receptor engages receptor interacting
RT   protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to
RT   activate NF-kappa B. Identification of a novel receptor-tyrosine
RT   kinase signalosome.";
RL   J. Biol. Chem. 276:8865-8874(2001).
RN   [33]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=11483589; DOI=10.1074/jbc.C100359200;
RA   Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III,
RA   Kufe D.;
RT   "The epidermal growth factor receptor regulates interaction of the
RT   human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.";
RL   J. Biol. Chem. 276:35239-35242(2001).
RN   [34]
RP   GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361;
RP   ASN-413; ASN-444; ASN-528; ASN-568 AND ASN-603, PHOSPHORYLATION AT
RP   THR-693; SER-991 AND SER-1026, AND MASS SPECTROMETRY.
RX   PubMed=16083266; DOI=10.1021/pr050113n;
RA   Wu S.L., Kim J., Hancock W.S., Karger B.;
RT   "Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS
RT   platform for high sequence coverage of complex proteins with extensive
RT   post-translational modifications-comprehensive analysis of beta-casein
RT   and epidermal growth factor receptor (EGFR).";
RL   J. Proteome Res. 4:1155-1170(2005).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-998; TYR-1069; TYR-1092;
RP   SER-1166 AND TYR-1172, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=15951569; DOI=10.1074/mcp.M500089-MCP200;
RA   Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,
RA   Lauffenburger D.A., White F.M.;
RT   "Time-resolved mass spectrometry of tyrosine phosphorylation sites in
RT   the epidermal growth factor receptor signaling network reveals dynamic
RT   modules.";
RL   Mol. Cell. Proteomics 4:1240-1250(2005).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-978, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Hepatoma;
RX   PubMed=16097034; DOI=10.1002/pmic.200401217;
RA   Gevaert K., Staes A., Van Damme J., De Groot S., Hugelier K.,
RA   Demol H., Martens L., Goethals M., Vandekerckhove J.;
RT   "Global phosphoproteome analysis on human HepG2 hepatocytes using
RT   reversed-phase diagonal LC.";
RL   Proteomics 5:3589-3599(2005).
RN   [37]
RP   INTERACTION WITH PELP1.
RX   PubMed=16140940; DOI=10.1158/0008-5472.CAN-05-0614;
RA   Vadlamudi R.K., Manavathi B., Balasenthil S., Nair S.S., Yang Z.,
RA   Sahin A.A., Kumar R.;
RT   "Functional implications of altered subcellular localization of PELP1
RT   in breast cancer cells.";
RL   Cancer Res. 65:7724-7732(2005).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-995;
RP   TYR-998; SER-1064; TYR-1069; TYR-1092; TYR-1110; TYR-1138; TYR-1172
RP   AND TYR-1197, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-869; TYR-1092; TYR-1172
RP   AND TYR-1197, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [40]
RP   TISSUE SPECIFICITY.
RX   PubMed=17671655; DOI=10.1172/JCI31680;
RA   Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D.,
RA   Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E.,
RA   Hoenderop J.G., Knoers N.V., Bindels R.J.;
RT   "Impaired basolateral sorting of pro-EGF causes isolated recessive
RT   renal hypomagnesemia.";
RL   J. Clin. Invest. 117:2260-2267(2007).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991; TYR-998; SER-1166;
RP   TYR-1069; TYR-1172 AND TYR-1197, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [43]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693 AND SER-991, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; THR-725;
RP   SER-991; SER-1025; SER-1026; SER-1037; SER-1039; SER-1042; SER-1064;
RP   SER-1081; SER-1166 AND TYR-1197, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; SER-991;
RP   THR-993; SER-995; TYR-998; SER-1039; THR-1041; SER-1042; SER-1045;
RP   SER-1064 AND SER-1166, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [49]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352; ASN-413 AND ASN-568,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-998; TYR-1016; TYR-1092;
RP   TYR-1110; TYR-1138; TYR-1172 AND TYR-1197, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [52]
RP   VARIANTS LUNG CANCER SER-719 AND ARG-858.
RX   PubMed=15118125; DOI=10.1126/science.1099314;
RA   Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S.,
RA   Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H.,
RA   Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M.;
RT   "EGFR mutations in lung cancer: correlation with clinical response to
RT   gefitinib therapy.";
RL   Science 304:1497-1500(2004).
RN   [53]
RP   VARIANTS LUNG CANCER ALA-709; LYS-709; ALA-719; ASP-719; CYS-719;
RP   SER-719; SER-724; LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL;
RP   PRO-748; 752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834;
RP   MET-858; ARG-858; GLN-861 AND GLU-873.
RX   PubMed=16533793; DOI=10.1158/1078-0432.CCR-05-1981;
RA   Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K.,
RA   Lam W.K., Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.;
RT   "Distinct epidermal growth factor receptor and KRAS mutation patterns
RT   in non-small cell lung cancer patients with different tobacco exposure
RT   and clinicopathologic features.";
RL   Clin. Cancer Res. 12:1647-1653(2006).
RN   [54]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-521; ARG-1034 AND VAL-1210.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for EGF, but also for other members of the EGF
CC       family, as TGF-alpha, amphiregulin, betacellulin, heparin-binding
CC       EGF-like growth factor, GP30 and vaccinia virus growth factor. Is
CC       involved in the control of cell growth and differentiation.
CC       Phosphorylates MUC1 in breast cancer cells and increases the
CC       interaction of MUC1 with SRC and CTNNB1/beta-catenin.
CC   -!- FUNCTION: Isoform 2 may act as an antagonist of EGF action.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Binds RIPK1. Interacts (via autophosphorylated C-terminal
CC       tail) with CBL. Part of a complex with ERBB2 and either PIK3C2A or
CC       PIK3C2B. Interacts (autophosphorylated form) with PIK3C2B; the
CC       interaction may be indirect. Interacts with PELP1. Binds MUC1.
CC       Interacts with AP2M1. Interacts with GAB2.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-297353, EBI-297353;
CC       Q29376:- (xeno); NbExp=1; IntAct=EBI-297353, EBI-1256881;
CC       P62157:CALM (xeno); NbExp=1; IntAct=EBI-297353, EBI-397403;
CC       P62158:CALM1; NbExp=1; IntAct=EBI-297353, EBI-397435;
CC       P62161:Calm1 (xeno); NbExp=2; IntAct=EBI-297353, EBI-397530;
CC       P62204:Calm1 (xeno); NbExp=1; IntAct=EBI-297353, EBI-397460;
CC       P22681:CBL; NbExp=1; IntAct=EBI-297353, EBI-518228;
CC       P22682:Cbl (xeno); NbExp=1; IntAct=EBI-297353, EBI-640919;
CC       P13987:CD59; NbExp=1; IntAct=EBI-297353, EBI-297972;
CC       P01133:EGF; NbExp=2; IntAct=EBI-297353, EBI-640857;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-297353, EBI-641062;
CC       P21860:ERBB3; NbExp=2; IntAct=EBI-297353, EBI-720706;
CC       Q15303:ERBB4; NbExp=2; IntAct=EBI-297353, EBI-80371;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-297353, EBI-401755;
CC       O00750:PIK3C2B; NbExp=4; IntAct=EBI-297353, EBI-641107;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-297353, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-297353, EBI-1341;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-297353, EBI-2264500;
CC       Q9UJ41:RABGEF1; NbExp=2; IntAct=EBI-297353, EBI-913954;
CC       Q13671:RIN1; NbExp=1; IntAct=EBI-297353, EBI-366017;
CC       P98083:Shc1 (xeno); NbExp=1; IntAct=EBI-297353, EBI-300201;
CC       P13866:SLC5A1; NbExp=3; IntAct=EBI-297353, EBI-1772443;
CC       Q8K424:Trpv3 (xeno); NbExp=2; IntAct=EBI-297353, EBI-2650739;
CC       P63104:YWHAZ; NbExp=1; IntAct=EBI-297353, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=p170;
CC         IsoId=P00533-1; Sequence=Displayed;
CC       Name=2; Synonyms=p60, Truncated, TEGFR;
CC         IsoId=P00533-2; Sequence=VSP_002887, VSP_002888;
CC       Name=3; Synonyms=p110;
CC         IsoId=P00533-3; Sequence=VSP_002889, VSP_002890;
CC       Name=4;
CC         IsoId=P00533-4; Sequence=VSP_002891, VSP_002892;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is also
CC       expressed in ovarian cancers.
CC   -!- PTM: Phosphorylation of Ser-695 is partial and occurs only if Thr-
CC       693 is phosphorylated.
CC   -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation;
CC       which does not affect tyrosine kinase activity or signaling
CC       capacity but may play a role in lysosomal targeting. Polyubiquitin
CC       linkage is mainly through 'Lys-63', but linkage through 'Lys-48',
CC       'Lys-11' and 'Lys-29' also occur.
CC   -!- DISEASE: Defects in EGFR are associated with lung cancer
CC       [MIM:211980].
CC   -!- MISCELLANEOUS: Binding of EGF to the receptor leads to
CC       dimerization, internalization of the EGF-receptor complex,
CC       induction of the tyrosine kinase activity, stimulation of cell DNA
CC       synthesis, and cell proliferation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/EGFR";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/egfr/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=EGFR entry;
CC       URL="http://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00588; CAA25240.1; -; mRNA.
DR   EMBL; U95089; AAB53063.1; -; mRNA.
DR   EMBL; U48722; AAC50802.1; -; mRNA.
DR   EMBL; U48723; AAC50804.1; -; Genomic_DNA.
DR   EMBL; U48724; AAC50796.1; -; Genomic_DNA.
DR   EMBL; U48725; AAC50797.1; -; Genomic_DNA.
DR   EMBL; U48726; AAC50798.1; -; Genomic_DNA.
DR   EMBL; U48727; AAC50799.1; -; Genomic_DNA.
DR   EMBL; U48728; AAC50800.1; -; Genomic_DNA.
DR   EMBL; U48729; AAC50801.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35786.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35787.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35788.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35789.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35790.1; -; Genomic_DNA.
DR   EMBL; AY698024; AAT97979.1; -; mRNA.
DR   EMBL; AY588246; AAS83109.1; -; Genomic_DNA.
DR   EMBL; AF277897; AAK01080.1; -; mRNA.
DR   EMBL; AF125253; AAG43240.1; -; mRNA.
DR   EMBL; AF125539; AAG43243.1; -; Genomic_DNA.
DR   EMBL; AF125538; AAG43243.1; JOINED; Genomic_DNA.
DR   EMBL; X06370; CAA29668.1; -; Genomic_DNA.
DR   EMBL; X00663; CAA25282.1; -; mRNA.
DR   EMBL; M38425; AAA63171.1; -; Genomic_DNA.
DR   EMBL; M11234; AAA52370.1; -; Genomic_DNA.
DR   IPI; IPI00018274; -.
DR   IPI; IPI00221346; -.
DR   IPI; IPI00221347; -.
DR   IPI; IPI00221348; -.
DR   PIR; A00641; GQHUE.
DR   RefSeq; NP_005219.2; -.
DR   RefSeq; NP_958439.1; -.
DR   RefSeq; NP_958440.1; -.
DR   RefSeq; NP_958441.1; -.
DR   UniGene; Hs.488293; -.
DR   PDB; 1DNQ; Model; -; A=25-336.
DR   PDB; 1DNR; Model; -; A=337-645.
DR   PDB; 1IVO; X-ray; 3.30 A; A/B=25-646.
DR   PDB; 1M14; X-ray; 2.60 A; A=695-1022.
DR   PDB; 1M17; X-ray; 2.60 A; A=695-1022.
DR   PDB; 1MOX; X-ray; 2.50 A; A/B=25-525.
DR   PDB; 1NQL; X-ray; 2.80 A; A=25-642.
DR   PDB; 1XKK; X-ray; 2.40 A; A=695-1022.
DR   PDB; 1YY9; X-ray; 2.60 A; A=25-642.
DR   PDB; 1Z9I; NMR; -; A=669-721.
DR   PDB; 2EB2; X-ray; 2.50 A; A=695-1022.
DR   PDB; 2EB3; X-ray; 2.84 A; A=695-1022.
DR   PDB; 2EXP; Model; -; A=311-326.
DR   PDB; 2EXQ; Model; -; A=27-536.
DR   PDB; 2GS2; X-ray; 2.80 A; A=696-1022.
DR   PDB; 2GS6; X-ray; 2.60 A; A=696-1022.
DR   PDB; 2GS7; X-ray; 2.60 A; A/B=696-1022.
DR   PDB; 2ITN; X-ray; 2.47 A; A=696-1019.
DR   PDB; 2ITO; X-ray; 3.25 A; A=696-1022.
DR   PDB; 2ITP; X-ray; 2.74 A; A=696-1022.
DR   PDB; 2ITQ; X-ray; 2.68 A; A=696-1022.
DR   PDB; 2ITT; X-ray; 2.73 A; A=696-1022.
DR   PDB; 2ITU; X-ray; 2.80 A; A=696-1022.
DR   PDB; 2ITV; X-ray; 2.47 A; A=696-1022.
DR   PDB; 2ITW; X-ray; 2.88 A; A=696-1022.
DR   PDB; 2ITX; X-ray; 2.98 A; A=696-1022.
DR   PDB; 2ITY; X-ray; 3.42 A; A=696-1022.
DR   PDB; 2ITZ; X-ray; 2.72 A; A=696-1022.
DR   PDB; 2J5E; X-ray; 3.10 A; A=696-1022.
DR   PDB; 2J5F; X-ray; 3.00 A; A=696-1022.
DR   PDB; 2J6M; X-ray; 3.10 A; A=696-1022.
DR   PDB; 2JIT; X-ray; 3.10 A; A/B=696-1022.
DR   PDB; 2JIU; X-ray; 3.05 A; A/B=695-1022.
DR   PDB; 2JIV; X-ray; 3.50 A; A/B=695-1022.
DR   PDB; 2KS1; NMR; -; B=634-677.
DR   PDB; 2RF9; X-ray; 3.50 A; A/B=696-1022.
DR   PDB; 2RFD; X-ray; 3.60 A; A/B=702-1022.
DR   PDB; 2RFE; X-ray; 2.90 A; A/B/C/D=702-1022.
DR   PDB; 2RGP; X-ray; 2.00 A; A=702-1016.
DR   PDB; 3B2U; X-ray; 2.58 A; A/B/E/I/M/P/S/V=335-538.
DR   PDB; 3B2V; X-ray; 3.30 A; A=25-642.
DR   PDB; 3BEL; X-ray; 2.30 A; A=702-1016.
DR   PDB; 3BUO; X-ray; 2.60 A; A/C=1063-1075.
DR   PDB; 3C09; X-ray; 3.20 A; A/D=335-538.
DR   PDB; 3G5V; X-ray; 2.00 A; C=311-326.
DR   PDB; 3G5Y; X-ray; 1.59 A; E=311-326.
DR   PDB; 3GOP; X-ray; 2.80 A; A=669-1022.
DR   PDB; 3GT8; X-ray; 2.96 A; A/B/C/D=696-1022.
DR   PDB; 3IKA; X-ray; 2.90 A; A/B=694-1022.
DR   PDB; 3OB2; X-ray; 2.10 A; A=1063-1074.
DR   PDBsum; 1DNQ; -.
DR   PDBsum; 1DNR; -.
DR   PDBsum; 1IVO; -.
DR   PDBsum; 1M14; -.
DR   PDBsum; 1M17; -.
DR   PDBsum; 1MOX; -.
DR   PDBsum; 1NQL; -.
DR   PDBsum; 1XKK; -.
DR   PDBsum; 1YY9; -.
DR   PDBsum; 1Z9I; -.
DR   PDBsum; 2EB2; -.
DR   PDBsum; 2EB3; -.
DR   PDBsum; 2EXP; -.
DR   PDBsum; 2EXQ; -.
DR   PDBsum; 2GS2; -.
DR   PDBsum; 2GS6; -.
DR   PDBsum; 2GS7; -.
DR   PDBsum; 2ITN; -.
DR   PDBsum; 2ITO; -.
DR   PDBsum; 2ITP; -.
DR   PDBsum; 2ITQ; -.
DR   PDBsum; 2ITT; -.
DR   PDBsum; 2ITU; -.
DR   PDBsum; 2ITV; -.
DR   PDBsum; 2ITW; -.
DR   PDBsum; 2ITX; -.
DR   PDBsum; 2ITY; -.
DR   PDBsum; 2ITZ; -.
DR   PDBsum; 2J5E; -.
DR   PDBsum; 2J5F; -.
DR   PDBsum; 2J6M; -.
DR   PDBsum; 2JIT; -.
DR   PDBsum; 2JIU; -.
DR   PDBsum; 2JIV; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 2RF9; -.
DR   PDBsum; 2RFD; -.
DR   PDBsum; 2RFE; -.
DR   PDBsum; 2RGP; -.
DR   PDBsum; 3B2U; -.
DR   PDBsum; 3B2V; -.
DR   PDBsum; 3BEL; -.
DR   PDBsum; 3BUO; -.
DR   PDBsum; 3C09; -.
DR   PDBsum; 3G5V; -.
DR   PDBsum; 3G5Y; -.
DR   PDBsum; 3GOP; -.
DR   PDBsum; 3GT8; -.
DR   PDBsum; 3IKA; -.
DR   PDBsum; 3OB2; -.
DR   ProteinModelPortal; P00533; -.
DR   DisProt; DP00309; -.
DR   DIP; DIP-405N; -.
DR   DIP; DIP-5764N; -.
DR   IntAct; P00533; 191.
DR   MINT; MINT-206389; -.
DR   STRING; P00533; -.
DR   GlycoSuiteDB; P00533; -.
DR   PhosphoSite; P00533; -.
DR   SWISS-2DPAGE; P00533; -.
DR   PeptideAtlas; P00533; -.
DR   PRIDE; P00533; -.
DR   Ensembl; ENST00000275493; ENSP00000275493; ENSG00000146648.
DR   GeneID; 1956; -.
DR   KEGG; hsa:1956; -.
DR   UCSC; uc003tqi.1; human.
DR   UCSC; uc003tqj.1; human.
DR   UCSC; uc003tqk.1; human.
DR   CTD; 1956; -.
DR   GeneCards; GC07P055054; -.
DR   H-InvDB; HIX0025338; -.
DR   HGNC; HGNC:3236; EGFR.
DR   HPA; CAB000035; -.
DR   HPA; HPA001200; -.
DR   HPA; HPA018530; -.
DR   MIM; 131550; gene.
DR   MIM; 211980; phenotype.
DR   Orphanet; 360; Glioblastoma.
DR   PharmGKB; PA7360; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P00533; -.
DR   OMA; MRRRHIV; -.
DR   PhylomeDB; P00533; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; arf6cyclingpathway; Arf6 signaling events.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; syndecan_3_pathway; Syndecan-3-mediated signaling events.
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_9417; Signaling by EGFR.
DR   DrugBank; DB00002; Cetuximab.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00317; Gefitinib.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB01269; Panitumumab.
DR   DrugBank; DB00072; Trastuzumab.
DR   NextBio; 7931; -.
DR   PMAP-CutDB; P00533; -.
DR   ArrayExpress; P00533; -.
DR   Bgee; P00533; -.
DR   Genevestigator; P00533; -.
DR   GermOnline; ENSG00000146648; Homo sapiens.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; NAS:UniProtKB.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070435; C:Shc-EGFR complex; ISS:BHF-UCL.
DR   GO; GO:0051015; F:actin filament binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003690; F:double-stranded DNA binding; NAS:UniProtKB.
DR   GO; GO:0005006; F:epidermal growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004710; F:MAP/ERK kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; IEA:InterPro.
DR   GO; GO:0043006; P:activation of phospholipase A2 activity by ...; TAS:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0016337; P:cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0001503; P:ossification; NAS:UniProtKB.
DR   GO; GO:0035413; P:positive regulation of catenin protein nucl...; IMP:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent pro...; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell prol...; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynt...; IDA:UniProtKB.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B sig...; IMP:BHF-UCL.
DR   GO; GO:0051205; P:protein insertion into membrane; TAS:UniProtKB.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphoryla...; IMP:UniProtKB.
DR   GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020762; Tyr_prot_kinase_EGF_rcpt.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF286; Tyr_prot_kinase_EGF_rcpt; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Isopeptide bond; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tumor suppressor; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25   1210       Epidermal growth factor receptor.
FT                                /FTId=PRO_0000016665.
FT   TOPO_DOM     25    645       Extracellular (Potential).
FT   TRANSMEM    646    668       Helical; (Potential).
FT   TOPO_DOM    669   1210       Cytoplasmic (Potential).
FT   REPEAT       75    300       Approximate.
FT   REPEAT      390    600       Approximate.
FT   DOMAIN      712    979       Protein kinase.
FT   NP_BIND     718    726       ATP (By similarity).
FT   COMPBIAS   1025   1071       Ser-rich.
FT   ACT_SITE    837    837       Proton acceptor (By similarity).
FT   BINDING     745    745       ATP (By similarity).
FT   SITE       1016   1016       Important for interaction with PIK3C2B.
FT   MOD_RES     678    678       Phosphothreonine; by PKC.
FT   MOD_RES     693    693       Phosphothreonine.
FT   MOD_RES     695    695       Phosphoserine.
FT   MOD_RES     725    725       Phosphothreonine.
FT   MOD_RES     869    869       Phosphotyrosine.
FT   MOD_RES     978    978       Phosphotyrosine.
FT   MOD_RES     991    991       Phosphoserine.
FT   MOD_RES     993    993       Phosphothreonine.
FT   MOD_RES     995    995       Phosphoserine.
FT   MOD_RES     998    998       Phosphotyrosine.
FT   MOD_RES    1016   1016       Phosphotyrosine.
FT   MOD_RES    1025   1025       Phosphoserine.
FT   MOD_RES    1026   1026       Phosphoserine.
FT   MOD_RES    1037   1037       Phosphoserine.
FT   MOD_RES    1039   1039       Phosphoserine.
FT   MOD_RES    1041   1041       Phosphothreonine.
FT   MOD_RES    1042   1042       Phosphoserine.
FT   MOD_RES    1045   1045       Phosphoserine.
FT   MOD_RES    1064   1064       Phosphoserine.
FT   MOD_RES    1069   1069       Phosphotyrosine.
FT   MOD_RES    1070   1070       Phosphoserine.
FT   MOD_RES    1071   1071       Phosphoserine.
FT   MOD_RES    1081   1081       Phosphoserine.
FT   MOD_RES    1092   1092       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1110   1110       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1138   1138       Phosphotyrosine.
FT   MOD_RES    1166   1166       Phosphoserine.
FT   MOD_RES    1172   1172       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1197   1197       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD     56     56       N-linked (GlcNAc...) (complex); atypical;
FT                                partial.
FT                                /FTId=CAR_000227.
FT   CARBOHYD    128    128       N-linked (GlcNAc...).
FT   CARBOHYD    175    175       N-linked (GlcNAc...).
FT   CARBOHYD    196    196       N-linked (GlcNAc...).
FT   CARBOHYD    352    352       N-linked (GlcNAc...).
FT   CARBOHYD    361    361       N-linked (GlcNAc...).
FT   CARBOHYD    413    413       N-linked (GlcNAc...).
FT   CARBOHYD    444    444       N-linked (GlcNAc...).
FT   CARBOHYD    528    528       N-linked (GlcNAc...).
FT   CARBOHYD    568    568       N-linked (GlcNAc...); partial.
FT   CARBOHYD    603    603       N-linked (GlcNAc...); partial.
FT   DISULFID     31     58
FT   DISULFID    157    187
FT   DISULFID    190    199
FT   DISULFID    194    207
FT   DISULFID    215    223
FT   DISULFID    219    231
FT   DISULFID    232    240
FT   DISULFID    236    248
FT   DISULFID    251    260
FT   DISULFID    264    291
FT   DISULFID    295    307
FT   DISULFID    311    326
FT   DISULFID    329    333
FT   DISULFID    337    362
FT   DISULFID    470    499
FT   DISULFID    506    515
FT   DISULFID    510    523
FT   DISULFID    526    535
FT   DISULFID    539    555
FT   DISULFID    558    571
FT   DISULFID    562    579
FT   DISULFID    582    591
FT   DISULFID    595    617
FT   DISULFID    620    628
FT   DISULFID    624    636
FT   CROSSLNK    716    716       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    737    737       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    754    754       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    867    867       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    929    929       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    970    970       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ     404    405       FL -> LS (in isoform 2).
FT                                /FTId=VSP_002887.
FT   VAR_SEQ     406   1210       Missing (in isoform 2).
FT                                /FTId=VSP_002888.
FT   VAR_SEQ     628    705       CTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFM
FT                                RRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLR ->
FT                                PGNESLKAMLFCLFKLSSCNQSNDGSVSHQSGSPAAQESCL
FT                                GWIPSLLPSEFQLGWGGCSHLHAWPSASVIITASSCH (in
FT                                isoform 3).
FT                                /FTId=VSP_002889.
FT   VAR_SEQ     628    628       C -> S (in isoform 4).
FT                                /FTId=VSP_002891.
FT   VAR_SEQ     629   1210       Missing (in isoform 4).
FT                                /FTId=VSP_002892.
FT   VAR_SEQ     706   1210       Missing (in isoform 3).
FT                                /FTId=VSP_002890.
FT   VARIANT      98     98       R -> Q (in dbSNP:rs17289589).
FT                                /FTId=VAR_019293.
FT   VARIANT     266    266       P -> R (in dbSNP:rs17336639).
FT                                /FTId=VAR_019294.
FT   VARIANT     521    521       R -> K (in dbSNP:rs2227983).
FT                                /FTId=VAR_019295.
FT   VARIANT     674    674       V -> I (in dbSNP:rs17337079).
FT                                /FTId=VAR_019296.
FT   VARIANT     709    709       E -> A (in lung cancer).
FT                                /FTId=VAR_026084.
FT   VARIANT     709    709       E -> K (in lung cancer).
FT                                /FTId=VAR_026085.
FT   VARIANT     719    719       G -> A (in lung cancer).
FT                                /FTId=VAR_026086.
FT   VARIANT     719    719       G -> C (in lung cancer;
FT                                dbSNP:rs28929495).
FT                                /FTId=VAR_026087.
FT   VARIANT     719    719       G -> D (in lung cancer).
FT                                /FTId=VAR_026088.
FT   VARIANT     719    719       G -> S (in lung cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019297.
FT   VARIANT     724    724       G -> S (in lung cancer).
FT                                /FTId=VAR_026089.
FT   VARIANT     734    734       E -> K (in lung cancer).
FT                                /FTId=VAR_026090.
FT   VARIANT     746    750       Missing (in lung cancer).
FT                                /FTId=VAR_026092.
FT   VARIANT     746    746       Missing (in lung cancer).
FT                                /FTId=VAR_026091.
FT   VARIANT     747    749       Missing (in lung cancer).
FT                                /FTId=VAR_026094.
FT   VARIANT     747    747       L -> F (in lung cancer).
FT                                /FTId=VAR_026093.
FT   VARIANT     748    748       R -> P (in lung cancer).
FT                                /FTId=VAR_026095.
FT   VARIANT     752    759       Missing (in lung cancer).
FT                                /FTId=VAR_026096.
FT   VARIANT     787    787       Q -> R (in lung cancer).
FT                                /FTId=VAR_026097.
FT   VARIANT     790    790       T -> M (in lung cancer).
FT                                /FTId=VAR_026098.
FT   VARIANT     833    833       L -> V (in lung cancer).
FT                                /FTId=VAR_026099.
FT   VARIANT     834    834       V -> L (in lung cancer).
FT                                /FTId=VAR_026100.
FT   VARIANT     858    858       L -> M (in lung cancer).
FT                                /FTId=VAR_026101.
FT   VARIANT     858    858       L -> R (in lung cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_019298.
FT   VARIANT     861    861       L -> Q (in lung cancer).
FT                                /FTId=VAR_026102.
FT   VARIANT     873    873       G -> E (in lung cancer).
FT                                /FTId=VAR_026103.
FT   VARIANT     962    962       R -> G (in dbSNP:rs17337451).
FT                                /FTId=VAR_019299.
FT   VARIANT     988    988       H -> P (in dbSNP:rs17290699).
FT                                /FTId=VAR_019300.
FT   VARIANT    1034   1034       L -> R (in dbSNP:rs34352568).
FT                                /FTId=VAR_042095.
FT   VARIANT    1210   1210       A -> V (in dbSNP:rs35918369).
FT                                /FTId=VAR_042096.
FT   MUTAGEN    1016   1016       Y->F: 50% decrease in interaction with
FT                                PIK3C2B. 65% decrease in interaction with
FT                                PIK3C2B; when associated with F-1197.
FT                                Abolishes interaction with PIK3C2B; when
FT                                associated with F-1197 and F-1092.
FT   MUTAGEN    1092   1092       Y->F: No change in interaction with
FT                                PIK3C2B. Abolishes interaction with
FT                                PIK3C2B; when associated with F-1197 and
FT                                F-1016.
FT   MUTAGEN    1110   1110       Y->F: No change in interaction with
FT                                PIK3C2B.
FT   MUTAGEN    1172   1172       Y->F: No change in interaction with
FT                                PIK3C2B.
FT   MUTAGEN    1197   1197       Y->F: No change in interaction with
FT                                PIK3C2B. 65% decrease in interaction with
FT                                PIK3C2B; when associated with F-1016.
FT                                Abolishes interaction with PIK3C2B; when
FT                                associated with F-1092 and F-1016.
FT   CONFLICT    540    540       N -> K (in Ref. 1; CAA25240).
FT   STRAND       40     43
FT   HELIX        44     55
FT   STRAND       59     63
FT   STRAND       65     67
FT   HELIX        77     81
FT   STRAND       84     87
FT   STRAND       89     93
FT   HELIX       101    103
FT   TURN        114    116
FT   STRAND      117    122
FT   STRAND      145    152
FT   HELIX       159    161
FT   TURN        164    167
FT   TURN        173    175
FT   STRAND      195    197
FT   STRAND      200    202
FT   TURN        203    205
FT   STRAND      211    215
FT   STRAND      224    229
FT   STRAND      236    238
FT   STRAND      241    247
FT   STRAND      249    256
FT   STRAND      259    263
FT   STRAND      267    271
FT   TURN        272    275
FT   STRAND      276    279
FT   STRAND      285    287
FT   STRAND      290    294
FT   STRAND      299    301
FT   STRAND      305    309
FT   STRAND      321    323
FT   STRAND      330    332
FT   STRAND      340    342
FT   HELIX       343    345
FT   HELIX       353    355
FT   HELIX       357    359
FT   STRAND      363    367
FT   STRAND      369    371
FT   HELIX       373    377
FT   TURN        380    383
FT   HELIX       389    397
FT   STRAND      400    403
FT   STRAND      405    408
FT   HELIX       418    420
FT   TURN        433    435
FT   STRAND      436    442
FT   STRAND      458    464
FT   HELIX       472    474
FT   HELIX       477    480
FT   STRAND      492    494
FT   HELIX       496    498
FT   TURN        499    503
FT   TURN        507    509
FT   STRAND      515    519
FT   STRAND      522    525
FT   STRAND      540    543
FT   STRAND      548    557
FT   STRAND      571    575
FT   STRAND      579    587
FT   STRAND      590    594
FT   STRAND      597    600
FT   STRAND      602    611
FT   STRAND      616    619
FT   STRAND      629    632
FT   TURN        633    635
FT   STRAND      704    706
FT   TURN        709    711
FT   STRAND      712    720
FT   STRAND      722    731
FT   STRAND      740    747
FT   HELIX       756    768
FT   STRAND      777    791
FT   HELIX       798    804
FT   STRAND      806    808
FT   HELIX       811    830
FT   HELIX       840    842
FT   STRAND      843    847
FT   STRAND      850    853
FT   HELIX       858    861
FT   TURN        862    865
FT   TURN        878    880
FT   HELIX       883    888
FT   HELIX       893    908
FT   TURN        914    917
FT   HELIX       920    922
FT   HELIX       923    929
FT   HELIX       941    950
FT   HELIX       955    957
FT   HELIX       961    973
FT   HELIX       975    978
FT   TURN        982    986
FT   HELIX       996   1002
FT   HELIX      1013   1016
SQ   SEQUENCE   1210 AA;  134277 MW;  D8A2A50B4EFB6ED2 CRC64;
     MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV
     VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA
     VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF
     QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC
     TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV
     VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK
     NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF
     ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL
     FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN
     LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM
     GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV
     ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS
     GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI
     CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA
     RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY
     GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK
     FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ
     QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED
     SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN
     TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV
     APQSSEFIGA
//
